Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:14 PM
Ignite Modification Date:
2025-12-24 @ 2:14 PM
NCT ID:
NCT01696695
Eligibility Criteria:
Inclusion Criteria:
* Participants with newly diagnosed mCRC who have started first-line capecitabine-based chemotherapy in accordance with the current Hungarian label
Exclusion Criteria:
* History of serious or unexpected reaction to fluoropyrimidine therapy
* Hypersensitivity to the active ingredient of Xeloda or to any of the excipients of the product, or to fluorouracil
* Known dihydropyrimidine dehydrogenase deficiency
* Pregnancy or lactation
* Inadequate bone marrow, hepatic or renal function
* Treatment with sorivudine or its chemical analogues (for example, brivudine)
* If any contraindication for any drug used in the combination treatment schedules is present, the drug in question cannot be used
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01696695
Study Brief:
Protocol Section:
NCT01696695